Loughborough University
Browse
Efficient Delivery of Transducing Polymer Nanoparticles for Gene-Mediated Induction of Osteogenesis for Bone Regeneration.pdf (2.83 MB)

Efficient delivery of transducing polymer nanoparticles for gene-mediated induction of osteogenesis for bone regeneration

Download (2.83 MB)
journal contribution
posted on 2023-02-23, 09:17 authored by Aveen Jalal JalalAveen Jalal Jalal, James E Dixon

Developing non-viral gene therapy vectors that both protect and functionally deliver nucleic acid cargoes will be vital if gene augmentation and editing strategies are to be effectively combined with advanced regenerative medicine approaches. Currently such methodologies utilize high concentrations of recombinant growth factors, which result in toxicity and off-target effects. Herein we demonstrate the use of modified cell penetrating peptides (CPPs), termed Glycosaminoglycan (GAG)-binding Enhanced Transduction (GET) peptides with plasmid DNA (pDNA) encapsulated poly (lactic-co-glycolic acid) PLGA nanoparticles (pDNA-encapsulated PLGA NPs). In order to encapsulate the pDNA, it was first condensed with a cationic low molecular weight Poly L-Lysine (PLL) into 30–60 nm NPs followed by encapsulation in PLGA NPs by double emulsion; yielding encapsulation efficiencies (EE) of ∼30%. PLGA NPs complexed with GET peptides show enhanced intracellular delivery (up to sevenfold) and transfection efficiencies (up to five orders of magnitude). Moreover, the pDNA cargo has enhanced protection from nucleases (such as DNase I) promoting their translatability. As an example, we show these NPs efficiently deliver pBMP2 which can promote osteogenic differentiation in vitro. Gene delivery to human Mesenchymal Stromal Cells (hMSCs) inducing their osteogenic programming was confirmed by Alizarin red calcium staining and bone lineage specific gene expression (Q RT-PCR). By combining simplistic and FDA-approved PLGA polymer nanotechnology with the GET delivery system, therapeutic non-viral vectors could have significant impact in future cellular therapy and regenerative medicine applications.

Funding

European Research Council under the European Community’s Seventh Framework Programme (FP7/2007– 2013)/ERC grant agreement 227845

Acellular Approaches for Therapeutic Delivery: UK Regenerative Medicine Platform Hub Application

Medical Research Council

Find out more...

History

School

  • Sport, Exercise and Health Sciences

Published in

Frontiers in Bioengineering and Biotechnology

Volume

8

Publisher

Frontiers Media

Version

  • VoR (Version of Record)

Rights holder

© The Authors

Publisher statement

This is an Open Access Article. It is published by Frontiers Media under the Creative Commons Attribution 4.0 International Licence (CC BY). Full details of this licence are available at: https://creativecommons.org/licenses/by/4.0/

Acceptance date

2020-07-01

Publication date

2020-08-05

Copyright date

2020

eISSN

2296-4185

Language

  • en

Depositor

Dr Aveen Jalal Jalal. Deposit date: 22 February 2023

Article number

849

Usage metrics

    Loughborough Publications

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC